Develop VacciDEEP declensional peptides for inducing protective immunity to hypervariable infectious disease pathogens such as H5N1 influenza, H1N1 influenza, and Dengue Fever.
Develop VacciDEEP declensional peptides as immunotherapy for solid tumor oncology indications such as melanoma, head and neck, glioma, pancreatic, ovarian and non-small cell lung cancers.
VacciDEEP declensional peptides encompass major polymorphism on head region of hemagluttinin envelope protein
A single dose of VacciDEEP declensional peptide induces a long-term T-cell memory response in healthy male volunteers without the use of adjuvant